Toxicity testing of new chemical substances is the mandatory scientific process used to identify human health and environmental hazards before a substance may be manufactured, imported, or placed on the market. Accredited third-party laboratories conduct these evaluations under Good Laboratory Practice (GLP) conditions in accordance with OECD Test Guidelines, GB national standards, and frameworks such as China's new chemical substance registration and the EU REACH regulation. This article outlines the sample types, testing items, methods, applications, and frequently asked questions related to new chemical substance toxicity determination.
Technical Overview
A new chemical substance is defined as any substance that is not listed on an existing chemical inventory, such as the Inventory of Existing Chemical Substances of China (IECSC), the United States TSCA Inventory, or the European EINECS. Before such a substance can be manufactured, imported, processed, or commercialized, regulators require systematic toxicity determination to characterize its potential hazards to human health and the environment. The resulting data form the scientific basis for registration dossiers, hazard classification, risk assessment, and the definition of appropriate control and protective measures.
Toxicity testing programs are typically tiered according to the anticipated or actual annual production or import volume of the substance. Low-volume tiers require a minimum data set covering acute health effects and basic aquatic toxicity, while higher tonnage tiers require repeated-dose toxicity, reproductive and developmental toxicity, toxicokinetics, and chronic environmental studies. Studies submitted for regulatory purposes must be performed in laboratories compliant with the OECD Principles of Good Laboratory Practice, and testing facilities are commonly accredited to ISO/IEC 17025 to demonstrate technical competence.
The outcome of toxicity determination feeds directly into Globally Harmonized System (GHS) classification and labeling, Safety Data Sheet authoring, persistence–bioaccumulation–toxicity (PBT) screening, occupational exposure assessment, and environmental release controls throughout the product life cycle.
Testing Samples
Research-Grade and Industrial-Grade New Substances
Newly synthesized organic or inorganic compounds intended for commercial notification represent the primary sample type. These substances should be supplied with a verified composition, a documented impurity profile, and a recommended purity level, generally not less than 98 percent for a mono-constituent substance. Multi-constituent substances and substances of unknown or variable composition (UVCBs) require additional compositional characterization to support the interpretation of toxicity results.
Intermediates, Monomers, and Reaction Products
Isolated or transported intermediates, monomers intended for polymerization, and reaction mass products frequently fall outside existing inventories and therefore require toxicity screening. Even when full registration is not triggered, acute aquatic toxicity and biodegradation data are commonly requested to assess environmental release scenarios during industrial handling.
New Polymers and Nanoforms
Polymeric substances not listed on the relevant inventory require evaluation unless they meet polymer-of-low-concern criteria, which consider number-average molecular weight, residual monomer content, and reactive functional groups. Substances manufactured at the nanoscale require supplementary characterization, including particle size distribution, agglomeration behavior, and surface chemistry, because these parameters strongly influence toxicological behavior.
Sample Submission Requirements
- Minimum quantity, typically from several tens of grams for a basic ecotoxicity package up to several kilograms for chronic and reproductive studies.
- Certificate of analysis stating purity, composition, and batch identification.
- Physicochemical information such as water solubility, vapor pressure, and stability under test and storage conditions.
- Handling instructions covering light sensitivity, hygroscopicity, oxidizing properties, and temperature control to ensure sample integrity and laboratory safety.
Testing Items
Human Health Hazard Endpoints
- Acute oral toxicity, reported as median lethal dose (LD50).
- Acute dermal toxicity and acute inhalation toxicity, reported as LD50 or median lethal concentration (LC50).
- Skin irritation and corrosion.
- Eye irritation and serious eye damage.
- Skin sensitization, evaluated in vivo or by defined in vitro approaches.
- Genotoxicity, including bacterial reverse mutation, in vitro chromosomal aberration, in vitro mammalian gene mutation, and in vivo micronucleus testing.
- Repeated-dose toxicity, including 28-day and 90-day studies with systemic and local endpoints.
- Reproductive and developmental toxicity, including screening studies, prenatal developmental toxicity, and extended one-generation studies.
- Toxicokinetics covering absorption, distribution, metabolism, and excretion (ADME).
Environmental Hazard Endpoints
- Algal growth inhibition, reported as 72-hour EC50 and no-observed-effect concentration.
- Daphnia acute immobilization, reported as 48-hour EC50.
- Fish acute toxicity, reported as 96-hour LC50.
- Chronic aquatic studies such as daphnia reproduction and fish early-life-stage toxicity.
- Ready biodegradability and inherent biodegradability.
- Bioaccumulation potential, expressed as the bioconcentration factor (BCF).
- Environmental fate studies, including hydrolysis, photolysis, and adsorption–desorption.
Supporting Physicochemical Parameters
- Water solubility, which governs test concentration feasibility for aquatic studies.
- n-Octanol–water partition coefficient, used to predict bioaccumulation potential.
- Vapor pressure, density, and particle size distribution, which influence exposure route selection.
- Stability in vehicle and test media, required for dose verification and analytical monitoring.
Testing Methods
In Vivo Toxicity Studies
Acute oral toxicity is most commonly conducted using the acute toxic class method or the up-and-down procedure described in OECD Test Guidelines 423 and 425, with equivalent national procedures in the GB/T 216xx series. Acute dermal and inhalation studies follow OECD Test Guidelines 402 and 403, respectively. Repeated-dose toxicity is evaluated under OECD Test Guidelines 407 (28-day) and 408 (90-day), while reproductive endpoints are addressed through OECD Test Guidelines 414, 421, 422, and 443. The local lymph node assay under OECD Test Guideline 429 remains the standard in vivo method for skin sensitization when alternative approaches are inconclusive.
In Vitro and Alternative Methods
Non-animal methods accepted by major regulatory frameworks include reconstructed human epidermis models for skin corrosion and irritation (OECD Test Guidelines 431 and 439), bovine cornea and isolated eye methods for eye hazard identification (OECD Test Guidelines 437, 438, and 492), and the defined approaches for skin sensitization combining chemistry-based and cell-based assays (OECD Test Guidelines 442C, 442D, and 442E). Genotoxicity screening relies on the bacterial reverse mutation test (OECD Test Guideline 471), the in vitro micronucleus test (OECD Test Guideline 487), and mammalian cell gene mutation assays (OECD Test Guidelines 476 and 490). These methods substantially reduce animal use while satisfying registration requirements when applied within validated applicability domains.
Ecotoxicity and Environmental Fate Methods
Aquatic toxicity is determined using OECD Test Guidelines 201 (algae), 202 (daphnia), and 203 (fish), with internationally harmonized equivalents published by ISO, such as ISO 8692, ISO 6341, and ISO 7346, and guidance such as ASTM E729 for acute toxicity testing. Biodegradability is assessed under OECD Test Guideline 301 series, bioaccumulation under OECD Test Guideline 305, and sediment or water transformation studies under OECD Test Guidelines 308 and 309. Chinese registration dossiers commonly reference the corresponding GB/T 218xx series of national standards for ecological effect testing.
Computational Approaches and Data Waivers
Where testing is scientifically unjustified or technically impossible, registrants may submit (Q)SAR predictions, read-across from structurally analogous substances, or weight-of-evidence arguments. Regulatory authorities review such justifications case by case, considering substance structure, exposure scenarios, and the reliability of the model or source data used.
Applications
- Registration of new chemical substances under China's environmental management framework, including record filing, simplified registration, and regular registration pathways.
- Preparation of registration dossiers under international chemicals legislation, such as REACH registrations and TSCA premanufacture notifications.
- GHS classification, labeling, and Safety Data Sheet authorization for hazardous communication compliance.
- Occupational health risk assessment and the establishment of workplace protective measures and handling procedures.
- Environmental risk assessment covering aquatic, sediment, and soil compartments, including PBT and vPvB screening.
- Internal product stewardship programs and safety evaluations during research, scale-up, and market entry of novel compounds.
FAQ
What minimum toxicity data set is typically required for a basic new chemical registration?
A basic tier generally includes acute oral toxicity, skin and eye irritation or corrosion, skin sensitization, bacterial reverse mutation, in vitro chromosomal aberration or micronucleus testing, and the three standard aquatic acute studies on algae, daphnia, and fish, together with ready biodegradability. Higher tonnage or high-hazard findings expand the requirement to repeated-dose, reproductive, and chronic environmental studies.
Must the studies be performed in GLP-compliant laboratories?
Yes. Data submitted for regulatory registration of new chemical substances must be generated in laboratories operating under the OECD Principles of Good Laboratory Practice, and many programs additionally recognize ISO/IEC 17025 accreditation as evidence of analytical competence. Non-GLP screening data may support internal decision-making but is generally not accepted for notification purposes.
Can in vitro or computational methods replace animal testing?
Validated in vitro methods are increasingly accepted, particularly for skin corrosion, skin irritation, eye hazard, and skin sensitization endpoints. Computational approaches such as (Q)SAR and read-across may be used to fill data gaps when scientifically justified. Definitive in vivo studies remain necessary for endpoints such as repeated-dose systemic toxicity and reproductive toxicity where no validated alternatives yet exist.
How much sample and time are required for a typical testing package?
A basic ecotoxicity and health hazard package usually requires several hundred grams of test substance and can be completed within a few months. Extended packages including 90-day repeated-dose or reproductive toxicity studies may require several kilograms and six months to one year, principally due to animal observation periods and histopathological evaluation.
Are there exemptions or reduced requirements for certain substances?
Yes. Polymers meeting polymer-of-low-concern criteria, substances used exclusively in closed research settings below specified quantity thresholds, and intermediates under strictly controlled conditions may qualify for simplified procedures or exemptions. Natural substances, non-isolated intermediates, and substances used solely as articles components are also commonly outside the scope of registration, although national rules differ and should be verified case by case.
